Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

US Treasury’s Final Earnings Stripping Guidance Keeps Pressure On Inversions

Executive Summary

The US Treasury released final guidance to eliminate one of the economic motivations behind inversion deals, the threat of which in April derailed the Pfizer/Allergan mega merger. It doesn’t, however, affect other practices as feared.


Related Content

Death And Tax Inversion: Policy Fight Won't Go Away, Now Spawning Lawsuits
The Fall Of Pfizergan: The Beginning, The End And Everything In Between
It's The End Of Pfizergan, So Pfizer Will Have To Grow It Alone
US Treasury Hits Back On Inversions; Will Pfizer Fold?
Inversion Crackdown: Does It Spell The End For Pfizer/AstraZeneca?


Related Companies